DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

Generator production for Tc-99m in Australia suspended following mechanical fault Expected to take weeks to repair

James Allison, Padmanee Sharma and Ramy Ibrahim ImaginAb appoints new members to scientific advisory board

Alliance completes deal for Piramal Imaging Expanding market presence in molecular imaging

Siemens announces first global installation of Biograph Vision PET/CT System yields better temporal resolution and sensitivity than previously reported

Cardinal Health showcases first integrated cloud solution for nuclear medicine at SNMMI Nuctrac replaces phone and fax orders

New PET tracer could help find cure for Alzheimer's Researchers from Yale show they can measure synaptic density: SNMMI

Spectrum Dynamics launches 12 detector SPECT system The VERITON SPECT system debuted at SNMMI

GE launched Syntermed's Emory Cardiac Toolbox at SNMMI Affordable option for users with older SPECT systems

Combined radionuclide therapy and immunotherapy shows promise New research unveiled at SNMMI meeting

SNMMI Exhibitor's Guide A few of the companies you'll want to visit with on the show floor

Made of the vital element manganese

MGH team develops a potential alternative to gadolinium-based contrast agents

par Lauren Dubinsky , Senior Reporter
A team at Massachusetts General Hospital developed an MR imaging agent that may be used as an alternative to gadolinium-based contrast agents.

In recent years there have been concerns over the health risks associated with gadolinium for certain patients, and the industry has been searching for safer options.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"There is a clear clinical need for gadolinium-free MR contrast agents," Peter Caravan, co-director of the Institute for Innovation in Imaging at MGH, told HCB News. "This is most apparent for patients with renal impairment, for whom GBCAs pose the risk of potentially devastating nephrogenic systemic fibrosis."

Caravan and his team developed a manganese-based agent called Mn-PyC3A. It can produce an MR signal comparable to that of GBCAs, and manganese is an essential element that the human body requires in small amounts.

The body naturally excretes excess manganese, but any gadolinium that is released from GBCAs is likely be retained in the body indefinitely. Studies have shown that it remains in the brain years after it was administered to the patient.

"The challenge with using manganese is being able to bind it tightly so that it is not released in the body, and to do this in a way that the strong MR signal remains," said Caravan. "Mn-PyC3A meets these requirements. Mn-PyC3A doesn't bind or interact with proteins or enzymes in the body, suggesting that its risk of causing adverse side effects is lower."

The team previously conducted mouse experiments and found that Mn-PyC3A provided good enhancement of blood vessels, liver and kidneys, and over 99 percent was excreted from the body within 24 hours by the liver and kidney.

In a more recent study published in Radiology, they compared the use of Mn-PyC3A to a commonly used GBCA in a baboon model. Each animal underwent two MR exams — one with Mn-PyC3A and one with the GBCA.

Once again, they found that the kidney and liver quickly excreted Mn-PyC3A and there was no evidence of the release of free manganese.

"Our MR contrast agent could replace GBCAs," said Caravan. "Mn-PyC3A was designed as a direct substitute for GBCAs, providing the same imaging results as GBCAs when used for the same disease indications. There are a number of studies that are needed for this replacement to happen."

They need to follow the FDA-mandated path to regulatory approval, which includes completing pre-clinical safety studies. Then they need to show in clinical trials that Mn-PyC3A is safe and provides the requisite diagnostic information.

"Once radiologists and referring physicians have experience showing that Mn-PyC3A provides the same diagnostic information as GBCAs and is safe to use, we think there will be widespread adoption of Mn-PyC3A," said Caravan.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2018 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS